KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Change in Receivables: 2009-2021

Historic Change in Receivables for Novavax (NVAX) over the last 11 years, with Dec 2021 value amounting to -$144.4 million.

  • Novavax's Change in Receivables rose 82.31% to -$356,000 in Q4 2016 from the same period last year, while for Dec 2016 it was -$2.1 million, marking a year-over-year increase of 75.56%. This contributed to the annual value of -$144.4 million for FY2021, which is 41.25% up from last year.
  • Novavax's Change in Receivables amounted to -$144.4 million in FY2021, which was up 41.25% from -$245.9 million recorded in FY2020.
  • Over the past 5 years, Novavax's Change in Receivables peaked at -$1.9 million during FY2017, and registered a low of -$245.9 million during FY2020.
  • For the 2-year period, Novavax's Change in Receivables averaged around -$195.1 million, with its median value being -$195.1 million (2020).
  • Data for Novavax's Change in Receivables shows a peak YoY surged of 41.25% (in 2021) over the last 5 years.
  • Novavax's Change in Receivables (Yearly) stood at -$1.9 million in 2017, then reached -$245.9 million in 2020, then surged by 41.25% to -$144.4 million in 2021.